 |
市场调查报告书
商品编码
1769046
化脓性汗腺炎市场:KOL的洞察KOL Insight - Hidradenitis Suppurativa |
||||||
本报告探讨了化脓性汗腺炎 (HS) 治疗领域不断发展变化的前景，并对现有和新兴疗法进行了全面分析。基于对12位关键意见领袖的访谈，报告探讨了TNF抑制剂（如修美乐）在生物相似药兴起背景下的关键作用、IL-17抑制剂（如优时比的Bimzelx）的广阔前景、口服JAK抑制剂（如Incyte的povorcitinib）带来的课题和机遇，以及它们在治疗方案中的地位。
对于希望了解不断变化的治疗格局并预测HS管理未来发展的医药专业人士而言，这项分析至关重要。
关键问题
- TNF抑制剂（如修美乐和类克）目前如何用于治疗化脓性汗腺炎，以及新疗法预计会带来哪些改变？
- 抗TNF生物相似药的研发如何影响HS市场的处方行为、可近性和定价？
- 诺华公司的IL-17A抑制剂Cosentyx的实际应用如何？专家预计其作用将如何改变？
- 优时比（UCB）的Bimzelx的最新临床数据与Cosentyx相比如何？预计它们将如何影响HS治疗格局？
- MoonLake Immunotherapeutics的soneloximab在IL-17治疗HS中可能发挥什么作用？
- Incyte公司的JAK1抑制剂povorcitinib与AbbVie公司的Rinvoq相比如何？在未来的临床实务中，它们可能如何进行序列分析或合併用药？
- 外用JAK抑制剂Opcella在HS治疗方案中处于什么位置？
- IL-1-αβ 抑制剂和 BTK 抑制剂等替代标靶在 HS 治疗中的治疗潜力。
- 在研产品必须达到哪些疗效、耐久性和安全性基准才能与现有的 TNF 和 IL-17 抑制剂竞争？
- 是否有任何后期药物可以弥补这些差距？
领导品牌
|
|
部分参与专家名单
- 多伦多大学医学院皮肤科教授兼系主任，多伦多女子学院医院皮肤科系主任
- 明尼苏达大学医学与皮肤科副教授
- 北卡罗来纳州温斯顿塞勒姆维克森林大学医学院皮肤病学、病理学和公共卫生科学教授
- 荷兰鹿特丹伊拉斯姆斯医学中心实验免疫皮肤病学教授
- 明尼苏达大学生物医学科学院临床教授丹麦哥本哈根
- 挪威北极大学皮肤病学和性病学教授，挪威博多Nordlandsykehuset皮肤病学主任
研究方法
"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，探讨关键疾病领域的当前和未来治疗前景。 KOL 的筛选标准非常严格，包括其全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都配有精心设计的讨论指南。这些指南由我们与 KOL 合作开发，并由行业专家进行同行评审，以确保所提问题全面且与当前市场动态相关。在每份报告发布后，我们会持续进行12个月的市场监测，并及时提供来自 KOL 的关于重要新闻事件、市场变化和市场发展的最新消息。
我们的报告有何独特之处？
FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入可行的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助我们的客户掌握新兴趋势，并有效应对复杂课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖 (KOL) 的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访谈和数据，以及持续的市场监测，让您能够全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域，包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入和其他领域问题的看法，使您能够做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。
This report delves into the evolving landscape of hidradenitis suppurativa (HS) treatment, providing a comprehensive analysis of current and emerging therapies. Based on insights from interviews with 12 KOLs, it explores the pivotal role of TNF inhibitors like Humira amidst the rise of biosimilars, the promising potential of IL-17 inhibitors, such as UCB's Bimzelx, and the challenges and opportunities presented by oral JAK inhibitors, including Incyte's povorcitinib, and their place in the treatment algorithm.
This analysis is crucial for pharmaceutical professionals aiming to navigate the evolving therapeutic landscape and anticipate future developments in HS management.
Key Questions Answered:
- How are TNF inhibitors like Humira and Remicade currently utilized in hidradenitis suppurativa treatment, and what changes are anticipated with newer therapies?
- What impact is the rollout of anti-TNF biosimilars having on prescribing behavior, access, and pricing dynamics in the HS market?
- What is the real-world uptake of Novartis' IL-17A inhibitor Cosentyx, and how do experts expect its role to evolve?
- How do the latest clinical data for UCB's Bimzelx compare with Cosentyx, and what is its expected impact on the HS treatment landscape?
- What is the potential role of MoonLake Immunotherapeutics' sonelokimab in the IL-17 treatment landscape for HS?
- How do Incyte's JAK1 inhibitor povorcitinib and AbbVie's Rinvoq compare, and how might they be sequenced or combined in future practice?
- Where does the topical JAK inhibitor Opzelura fit into the HS treatment algorithm?
- What are the therapeutic potentials of alternative targets like IL-1-alpha-beta inhibition and BTK inhibition in HS treatment?
- What efficacy, durability, and safety benchmarks must pipeline products achieve to compete with established TNF and IL-17 inhibitors?
- What key unmet needs persist in HS, and are any late-stage agents poised to address these gaps?
Key Brands:
|
|
Partial List of Participating Experts:
- Professor and Director of the Departmental Division for Dermatology, Department of Medicine at the University of Toronto and Division Head of Dermatology at Women's College Hospital, Toronto
- Associate Professor of Internal Medicine & Dermatology at the University of Minnesota, MN
- Professor of Dermatology, Pathology and Public Health Sciences at the Wake Forest University School of Medicine, Winston-Salem, NC
- Professor in Experimental Immunodermatology, Erasmus MC, Rotterdam, Netherlands
- Clinical Professor, Department of Biomedical Sciences, University of Copenhagen, Denmark
- Head Physician, Dermatologist, Nordlandssykehuset Bodo, Professor of Skin and Venereal Diseases, The Arctic University of Norway, Norway
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
